Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bengt Jönsson

Showing results (1-10 of 132) with videos related to

Pageof 14
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 27, 2011
Relative effectiveness and the European pharmaceutical marketBengt Jönsson
Evidence-Based Medicine|February 8, 2011
A 3-year lifestyle intervention for adults at moderate to high risk of cardiovascular disease is cost effective when added to standard care and improves physical health-related quality of lifeBengt Jönsson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 20, 2007
Economic evaluation for pharmaceuticals in GermanyBengt Jönsson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Technology assessment for new oncology drugsBengt Jönsson
Pharmacoeconomics|May 7, 2005
Changing health environment: the challenge to demonstrate cost-effectiveness of new compoundsBengt Jönsson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 28, 2016
Disruptive innovation and EU health policyBengt Jönsson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 21, 2009
Ten arguments for a societal perspective in the economic evaluation of medical innovationsBengt Jönsson
Molecular Oncology|December 3, 2014
Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug developmentBengt Jönsson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 23, 2008
IQWiG: an opportunity lost?Bengt Jönsson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 1, 2014
Commentary : On Drummond's "Time for a change in drug licensing requirements?"Bengt Jönsson
Pageof 14

Showing results (1-10 of 132) with videos related to

Sort By:
Pageof 14
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 27, 2011
Relative effectiveness and the European pharmaceutical marketBengt Jönsson
Evidence-Based Medicine|February 8, 2011
A 3-year lifestyle intervention for adults at moderate to high risk of cardiovascular disease is cost effective when added to standard care and improves physical health-related quality of lifeBengt Jönsson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 20, 2007
Economic evaluation for pharmaceuticals in GermanyBengt Jönsson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2013
Technology assessment for new oncology drugsBengt Jönsson
Pharmacoeconomics|May 7, 2005
Changing health environment: the challenge to demonstrate cost-effectiveness of new compoundsBengt Jönsson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|October 28, 2016
Disruptive innovation and EU health policyBengt Jönsson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|July 21, 2009
Ten arguments for a societal perspective in the economic evaluation of medical innovationsBengt Jönsson
Molecular Oncology|December 3, 2014
Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug developmentBengt Jönsson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 23, 2008
IQWiG: an opportunity lost?Bengt Jönsson
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 1, 2014
Commentary : On Drummond's "Time for a change in drug licensing requirements?"Bengt Jönsson
Pageof 14